UNICYCIVE THERAPEUTICS, INC. Incremental Common Shares Attributable to Dilutive Effect of Equity Forward Agreements
UNICYCIVE THERAPEUTICS, INC. (UNCY) had Incremental Common Shares Attributable to Dilutive Effect of Equity Forward Agreements of 438.37 thousand shares as of 2021-07-13, per its 10-Q filed 2023-11-14.
Discontinued › Notes
us-gaap:IncrementalCommonSharesAttributableToEquityForwardAgreements · last filed 2023-11-14
- 2021-07-13: Incremental Common Shares Attributable to Dilutive Effect of Equity Forward Agreements 438.37K shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Equity Forward Agreements |
|---|---|
| 2021-07-13 | 438.37K shares 10-Q · filed 2023-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |